Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 72 post-ruxolitinib window

Oura Digital Twin Dashboard

Oura Gen 4: 2026-01-08 to 2026-05-26 (139 unique days, 156 sleep periods) · 9/10 analysis modules loaded · Ruxolitinib 10 mg BID from 2026-03-16

Generated 2026-05-28 07:29 · Post-HSCT Patient

POST-HSCT BIOMETRIC MONITORING

Consumer wearable suggests a physiological shift after JAK inhibitor start
exploratory N=1 monitoring in a confounded window

N/A

Lowest raw
p-value

N/A

FDR-adjusted
q-value

0/0

Streams surviving
FDR correction

88,921

Biometric readings
analyzed

Oura Ring Gen 4 · 139 days · 9/10 analysis modules · Ruxolitinib 10 mg BID from 2026-03-16

PRE

Pre-Ruxolitinib

67 days · 73 sleep periods

HR 85.1 bpm HRV 9.1 ms

POST

Post-Ruxolitinib

72 days · 83 sleep periods

HR 74.7 bpm HRV 23.0 ms

Key Finding
Analysis modules detected multiple biosignal shifts after ruxolitinib initiation, but the 72-day post-intervention window remains too short for strong causal claims. 0/0 CausalImpact streams reach raw p<0.05; 0/0 survive FDR correction. Separate UKF comparisons: Cardiac Reserve shift p<0.001, Sleep Quality shift p<0.001.

Temperature

N/A

No data

HRV (RMSSD)

16.3ms

vs healthy 42-49 ms | Kleiger 1987 / Bigger 1992

Resting HR

80bpm

IST threshold: 90 bpm

SpO2

96.1%

BOS risk: LOW (13/100)

Sleep Efficiency

74%

Below 85% threshold

Autonomic Tone

0.00SD

UKF state | improved | p<0.001

GVHD Score

24/100

7d avg: 34

Anomaly Days

14/156

Feb 9 detected (14 anomaly days, N=1)

Interrupted Time Series: Temperature Response

CausalImpact BSTS

Treatment Effect Sizes

CausalImpact + UKF

Disease State Trajectory

rSLDS 4-State Model

Anomaly Detection

5-Algorithm Ensemble

Composite Biomarker Trends

6 Biomarkers

SpO2 & BOS Risk

Pulmonary Screening

Combined Biosignal Timeline

5-Channel View

Heart Rate Terrain Map

3D Surface

Phase Space Reconstruction

Nonlinear Dynamics

Sleep Architecture Heatmap

Epoch-Level

Circadian Rhythm Analysis

Cosinor Model

Methodology & Data Provenance

Data Source

Oura Ring Gen 4 (continuous PPG, accelerometry, thermometry)

Volume

78,109 HR readings · 10,812 HRV samples · 12,553 sleep epochs

Analysis Pipeline

CausalImpact (BSTS) · Unscented Kalman Filter (5 latent states) · rSLDS (4 disease states) · 5-algorithm anomaly ensemble · 6 composite biomarkers · Chronos-2 / ARIMA forecasting

Sleep Architecture

Deep: 14.5% Light: 53.1% REM: 11.6% Awake: 20.8%

For research and clinical discussion only. Not a diagnostic tool. All p-values are exploratory.

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – May 26, 2026 · Post-intervention: 72 days (ruxolitinib, March 16)